Medical Education Library

Controlling Emesis: Evolving Challenges, Novel Strategies


 

Duke University School of Nursing, Durham, North Carolina, and University of Cincinnati Hospital, Cincinnati, Ohio

Continued research over the past 25 years has led to steady progress in the management of nausea and vomiting among patients with cancer undergoing emetogenic chemotherapy, radiation therapy, or surgery. This review of antiemetic therapy discusses the evolution and improvement in treatment options available, the identification of risk factors for acute and delayed nausea and vomiting, and the development of alternative drug delivery systems and their impact on patient compliance and convenience.

Recommended Reading

Farletuzumab (MORAb-003) in platinum-sensitive ovarian cancer patients experiencing a first relapse
MDedge Hematology and Oncology
Bisphosphonates May Reduce Breast Cancer Risk
MDedge Hematology and Oncology
A randomized phase III trial of BIBW 2992 versus chemotherapy as first-line treatment for stage IIIB/IV adenocarcinoma of the lung harboring an epidermal growth factor receptor-activating mutation
MDedge Hematology and Oncology
Lymphadenectomy and Cervical Cancer
MDedge Hematology and Oncology
Exercise Is Safe for Cancer Patients, Survivors
MDedge Hematology and Oncology
Head & Neck Cancers
MDedge Hematology and Oncology
Second-line CML drugs prove better than first
MDedge Hematology and Oncology
Phase 3 trial of pixantrone leaves FDA uneasy
MDedge Hematology and Oncology
ODAC votes against one leukemia, one NHL drug
MDedge Hematology and Oncology
Denileukin diftitox has significant, durable responses in CTCL
MDedge Hematology and Oncology